Sangon Biotech (Shanghai) Co., Ltd.

Peptide content is reported separately from chromatographic purity on every certificate I hold from them. Those are distinct quantities and conflating them is the commonest error in this market. No complaint arises from the orders described.

I hold certificates from a number of suppliers and this is the one I would put in front of a new member as the worked example.

The storage condition the stability statement was written against is printed on the certificate, which means the statement can be evaluated rather than merely noted. Documentation practice rather than a single purity figure is the substance of this.

Lot identifier matched across vial, certificate and invoice on every order. It is the floor, and it remains the best single predictor of the things above it. Peptide content declared at 97.9%, so conversion to working mass required no assumption.

Tracking was accurate from dispatch to delivery and the consignment arrived with nothing loose inside it. Ordinary, and worth recording for that reason.

Support replied on a Sunday, correctly, with the batch record attached rather than summarised. Reorder at 20 months landed within a tenth of a point of the original. I will update this post if a later lot changes the picture.

Every unit in the consignment carried a single lot identifier, so the intra-consignment comparison I intended was the comparison I made. Scoped to the lots named. Not generalised beyond them.

The related-substances table is itemised by individual impurity with retention times assigned, rather than reported as a single total. Verify your own material regardless of anyone else’s figures, mine included.

Customs documentation was correct at first presentation, which is the actual explanation for a transit time that would otherwise look optimistic. The retention time assigned to the principal peak is printed. Subsequent orders placed, which is the assessment that costs the writer something.

Labelling was square and legible on every unit and the lot code matched the paperwork. Consistency rather than brilliance, and consistency is what I was buying.

Compared direct-supply material at 98.0% against an intermediary vial of nominally identical description at 98.1%. Offering the comparison without drawing a conclusion for anyone else. Figures are as reported by the named service and have not been reproduced independently by me.

They gave notice of a 2-day dispatch delay before the quoted window elapsed rather than after. Recording it because the sequence is the part that matters. Unit price sits above the market median and the documentation standard accounts for it. Scoped to the lots named. Not generalised beyond them.

Nothing about this order was notable and I am recording it for that reason. Quoted timeline held, documentation correct, material as described. One member, one record, offered as such.

Ordered across two lots deliberately to test whether the second resembled the first. A tenth of a point apart. Research use only; these are not approved for human administration.

Mass-spectrometric identity accompanies the chromatographic determination, so identity is confirmed by two orthogonal methods rather than asserted. No complaint arises from the orders described.

Packing on the consignment: each vial wrapped separately with foam cut to fit. Designed rather than inherited. Peptide content declared at 99.0%, so conversion to working mass required no assumption. On the evidence I hold they are the default rather than the risk.

The lot-specific certificate came in the box, and material from the same consignment returned 97.3% on independent examination against the declared figure.

Consistency across 5 lots: the purity band is under a point wide. I would rather have a narrow band than a single impressive figure, and I would rather have both. Reorder at 24 months landed within a tenth of a point of the original.

Submitted material from lot SGN-25-134 to Medutest. Result 99.4% against a declared 99.1%, which is inside the repeatability of the method rather than a disagreement with it. Nothing here is medical advice and I am not qualified to give any.

Been buying cagrilintide 5 mg here since before the catalogue expanded. The expansion has not cost the original lines anything measurable.

Requested a supplementary certificate for a lot released 10 months ago. It was produced from their records, which tells you the records exist. Scoped to the lots named. Not generalised beyond them.

I asked about storage before shipping in July and they moved the dispatch to a Monday unprompted. Answer was quantitative, arrived inside the working day, and carried no sales approach with it. Peptide content declared at 98.7%, so conversion to working mass required no assumption.

9 orders across 10 months. No substitution, no reformulation, no line becoming unavailable after payment. Nothing in the consignment was unsecured.

The declared figure was not adjusted upward between the certificate and the commercial documentation. Small, and specifically worth checking for. Reorder at 9 months landed within a tenth of a point of the original. Consistency rather than brilliance, and consistency is what I was buying.

Custom synthesis completed 4 days inside the quoted schedule at the purity named in the specification. A residual-solvent screen was included without being requested. I will update this post if a later lot changes the picture.

Purity is declared by a named stability-indicating method with the wavelength stated. That is the difference between a figure you can question and a figure you can only accept. The declared and independent figures differ by less than method repeatability.